HOME > TOP STORIES

TOP STORIES

BUSINESS Growth of Global Products Outstrips Abilify Drop in Jan.-June: Otsuka

August 9, 2017
BUSINESS Astellas Looks to Be First to Market in HIF-PH Inhibitor Space

August 8, 2017
ACADEMIA NCCHD to Launch Panel to Study Real-World Drug Use in Children, Findings Might Be Used for Label Revisions

August 8, 2017
TRENDS Top Drugs Jostling for Higher Share amid Tepid Market, Trulicity Overtakes Victoza in GLP Space: April-June

August 7, 2017
REGULATORY (Update) Katsunobu Kato Tapped as New Health Minister

August 4, 2017
REGULATORY Katsunobu Kato Tapped as New Health Minister

August 3, 2017
REGULATORY “We Should Increase Our Efforts” to Promote Pharmaceutical Industry: New Health Policy Bureau Chief Takeda

August 3, 2017
ACADEMIA Drug Vial Optimization Reduces Drug Expenditure, with Biggest Savings for Opdivo: Study

August 2, 2017
REGULATORY MHLW to Support Healthcare-Related Startups from “Long-Term Perspective”: Health Minister Shiozaki

August 1, 2017
REGULATORY Drug Pricing Overhaul Must Strike Balance between Benefits and Costs: Health Insurance Bureau Chief

July 31, 2017
BUSINESS Chugai Nets Half-Year Revenue Rise on Milestone Income

July 28, 2017
REGULATORY Chuikyo Scrutiny Continues for Cost Calculation Pricing Formula

July 27, 2017
REGULATORY Chuikyo Members at Odds over How to Proceed with “CEA” Debate

July 27, 2017
BUSINESS Linzess Off to Solid Start, Astellas Eyes Big Indication Addition

July 26, 2017
BUSINESS Novartis Japan Revenue Nearly Hit Bottom, FY2016 Sales Down 3.7%: New Chief

July 25, 2017
BUSINESS (Update) Mitsubishi Tanabe to Buy Israel’s NeuroDerm for US$1.1 Billion

July 25, 2017
BUSINESS Mitsubishi Tanabe to Buy Israel’s NeuroDerm for US$1.1 Billion

July 24, 2017
BUSINESS Asahi Kasei Pharma to Expand Lineup in Orthopedic Field, Boost Osteoporosis Market Share through Once-Yearly Formulation of Reclast

July 24, 2017
ACADEMIA Hypertension Treatment Guidelines for Elderly Finalized with Recommendations on Dosage Reduction, Discontinuation

July 21, 2017
REGULATORY Panel OKs 42.12 Million Yen Price Tag for Drug Makers’ MID-NET Use in PMS

July 20, 2017

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…